Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 3/20 | 0.42 |
| ▸ | ITGAV | P06756 | 15/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 14/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.38 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.38 |
| ▸ | ITGB5 | P18084 | 4/20 | 0.35 |
| ▸ | ITGB6 | P18564 | 4/20 | 0.35 |
| ▸ | ITGB8 | P26012 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19544248 | 0.95 | CXCR4 (0.39) | CXCR4ITGAVITGB3ITGA2BUHRF1 | |
| SCHEMBL12572838 | 0.89 | CXCR4 (0.34) | CXCR4ITGAVITGB3ITGA2B | |
| SCHEMBL325378 | 0.82 | CXCR4 (0.39) | CXCR4ITGAVITGB3ITGA2BITGB5 | |
| SCHEMBL21715684 | 0.82 | ITGAV (0.40) | CXCR4ITGAVITGB3ITGA2BITGB5 | |
| SCHEMBL4530325 | 0.82 | ITGAV (0.43) | CXCR4ITGAVITGB3ITGA2BITGB5 | |
| SCHEMBL8354537 | 0.80 | ITGAV (0.41) | CXCR4ITGAVITGB3ITGB6ITGB8 | |
| SCHEMBL4762028 | 0.78 | ITGB3 (0.50) | ITGAVITGB3ITGA2BITGB5ITGB6 | |
| SCHEMBL16668608 | 0.78 | CXCR4 (0.36) | CXCR4ITGAVITGB3ITGA2BITGB5 | |
| SCHEMBL19056917 | 0.78 | SRC (0.32) | CXCR4 | |
| SCHEMBL21715687 | 0.77 | ITGAV (0.39) | CXCR4ITGAVITGB3ITGB5ITGB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024145245-A2 | ALPHA-V-BETA-8 INTEGRIN INHIBITORS AND USES THEREOF | PLIANT THERAPEUTICS, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
| US-11827621-B2 | Inhibitors of (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827621-B2 | Inhibitors of (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230365556-A1 | N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-11795167-B2 | Inhibitors of (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11795167-B2 | Inhibitors of (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11673887-B2 | N-acyl amino acid compounds and methods of use | PLIANT THERAPEUTICS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-11639353-B2 | Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-05-02 | — | — | US | disclosed |
| US-11639353-B2 | Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-05-02 | — | — | US | disclosed |
| US-11345676-B2 | Apoptosis signal-regulating kinase 1 (ASK 1) inhibitor compounds | PHARMAKEA, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-9931407-B2 | Silicon based drug conjugates and methods of using same | BLINKBIO, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2017-07-20 | — | — | US | disclosed |
| WO-2016183359-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. (US) | 2016-11-17 | — | — | WO | disclosed |
| US-8133896-B2 | Pyrimidine derivatives which are antagonist of the vitronectin receptor | GALAPAGOS NV (BE) | 2012-03-13 | — | — | US | disclosed |
| WO-2011060395-A1 | CYCLIC UREAS USEFUL AS HIV INHIBITORS | SCHERING CORPORATION (US) | 2011-05-19 | — | — | WO | disclosed |
| US-20110039867-A1 | PYRIMIDINE DERIVATIVES WHICH ARE ANTAGONIST OF THE VITRONECTIN RECEPTOR | GALAPAGOS SAS | 2011-02-17 | — | — | US | disclosed |
| US-20080045521-A1 | PHENYLALANINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | US | disclosed |
| US-20070219233-A1 | Antitumor, antiinflammatory, antiarthritic agents, treating metastasis, restenosis, osteoporosis, macular degeneration, and diabetic retinopathy; 7-(2-{1-[1-(3-Benzyloxy-phenyl)-2-ethoxycarbonyl-vinyl]-1H-indol-5-yloxy}-ethyl)-3,4-dihydro-2H-[1,8]naphthyridine-1-carboxylic acid tert-butyl ester | LU TIANBO | 2007-09-20 | — | — | US | disclosed |
| US-7241789-B2 | Substituted indoles and their use as integrin antagonists | 3-DIMENSIONAL PHARMACEUTICAL, INC. (US) | 2007-07-10 | — | — | US | disclosed |
| US-6881736-B1 | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2005-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219233-A1 | Antitumor, antiinflammatory, antiarthritic agents, treating metastasis, restenosis, osteoporosis, macular degeneration, and diabetic retinopathy; 7-(2-{1-[1-(3-Benzyloxy-phenyl)-2-ethoxycarbonyl-vinyl]-1H-indol-5-yloxy}-ethyl)-3,4-dihydro-2H-[1,8]naphthyridine-1-carboxylic acid tert-butyl ester | ITGA5, ADGRE5, ITGAV | CXCR4 45/4885ITGAV 3/4885ITGB3 10/4885 |
| US-20080045521-A1 | PHENYLALANINE DERIVATIVES | ITGB5, ITGB1, ITGA2B | CXCR4 2520/4885ITGAV 17/4885ITGB3 6/4885 |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | CXCR4 2552/4885ITGAV 574/4885ITGB3 454/4885 |
| US-20110039867-A1 | PYRIMIDINE DERIVATIVES WHICH ARE ANTAGONIST OF THE VITRONECTIN RECEPTOR | P2RY1, P2RY2, P2RX5 | CXCR4 112/4885ITGAV 492/4885ITGB3 273/4885 |
| US-11673887-B2 | N-acyl amino acid compounds and methods of use | ITGA1, ITGB1, ITGAL | CXCR4 1019/4885ITGAV 4/4885ITGB3 9/4885 |
| US-11827621-B2 | Inhibitors of (α-v)(β-6) integrin | ITGB6, ITGA6, ITGAV | CXCR4 429/4885ITGAV 3/4885ITGB3 12/4885 |
| US-11795167-B2 | Inhibitors of (α-v)(β-6) integrin | ITGB6, ITGA6, ITGAV | CXCR4 470/4885ITGAV 3/4885ITGB3 11/4885 |
| US-11639353-B2 | Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors | ITGB1, ITGB2, ITGA1 | CXCR4 55/4885ITGAV 4/4885ITGB3 6/4885 |
| US-20230365556-A1 | N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE | ITGA1, ITGB1, ITGAL | CXCR4 1019/4885ITGAV 4/4885ITGB3 9/4885 |
| US-11345676-B2 | Apoptosis signal-regulating kinase 1 (ASK 1) inhibitor compounds | BAX, BAD, BCL2 | CXCR4 3989/4885ITGAV 4843/4885ITGB3 4646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.